The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The cancer-associated Sm-like (CaSm) oncogene is overexpressed in 87% of human pancreatic tumor samples and CaSm knockdown has demonstrated therapeutic efficacy in murine models of pancreatic cancer. Evidence indicates that CaSm modulates messenger RNA degradation; however, its target genes and the mechanisms by which CaSm promotes pancreatic cancer remain largely unknown. Here, we demonstrate that the CaSm overexpression alters several hallmarks of cancer—including transformation, proliferation, chemoresistance and metastasis. Doxycycline-induced CaSm expression enhanced proliferation and both anchorage-dependent and -independent growth of the human Panc-1 cells in vitro. CaSm induction decreased gemcitabine-induced cytotoxicity and altered the expression of apoptotic regulation genes, including Bad, E2F1 and Bcl-X L. CaSm-overexpressing Panc-1 cells were twofold more migratory and fourfold more invasive than the driver controls and demonstrated characteristics of epithelial-to-mesenchymal transition such as morphological changes and decreased E-cadherin expression. CaSm induction resulted in changes in RNA expression of metastasis-associated genes such as MMP1, SerpinB5, uPAR and Slug. Using a murine model of metastatic pancreatic cancer, injection of CaSm-induced Panc-1 cells resulted in a higher abundance of hepatic metastatic lesions. Overall, CaSm overexpression contributed to a more aggressive cancer phenotype in Panc-1 cells, further supporting the use of CaSm as a therapeutic target against pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In mammals, Lsm1 dysregulation is linked to tumorigenesis and immune programs [29–31].”
From The Lsm1–7 complex couples 3′-end protection to histone H4 acetylation to maintain mRNA homeostasis in Fusarium graminearum (2026) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Research works printed but not linked: 41
- Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413. · DOI · Paper page
- Thota R, Pauff JM, Berlin JD . Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park) 2014; 28: 70–74.
- Arshad A, Al-Leswas D, Al-Taan O, Stephenson J, Metcalfe M, Steward WP et al. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. Am J Clin Oncol 2011; 36: 411–414. · doi:10.1097/coc.0b013e3182124216
- Shi S, Yao W, Xu J, Long J, Liu C, Yu X . Combinational therapy: new hope for pancreatic cancer? Cancer Lett 2012; 317: 127–135. · DOI
- Conroy T, Gavoille C, Adenis A . Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol 2011; 23: 390–395. · DOI
- Schweinfest CW, Graber MW, Chapman JM, Papas TS, Baron PL, Watson DK . CaSm: an Sm-like protein that contributes to the transformed state in cancer cells. Cancer Res 1997; 57: 2961–2965.
- Bouveret E, Rigaut G, Shevchenko A, Wilm M, Seraphin B . A Sm-like protein complex that participates in mRNA degradation. EMBO J 2000; 19: 1661–1671. · DOI · Paper page
- Ingelfinger D, Arndt-Jovin DJ, Luhrmann R, Achsel T . The human LSm1-7 proteins colocalize with the mRNA-degrading enzymes Dcp1/2 and Xrnl in distinct cytoplasmic foci. RNA 2002; 8: 1489–1501. · DOI · Paper page
- Sheth U, Parker R . Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science 2003; 300: 805–808. · DOI · Paper page
- Tharun S . Roles of eukaryotic Lsm proteins in the regulation of mRNA function. Int Rev Cell Mol Biol 2009; 272: 149–189. · DOI
- Tharun S, He W, Mayes AE, Lennertz P, Beggs JD, Parker R . Yeast Sm-like proteins function in mRNA decapping and decay. Nature 2000; 404: 515–518. · DOI · Paper page
- Fraser MM, Watson PM, Fraig MM, Kelley JR, Nelson PS, Boylan AM et al. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. Cancer Res 2005; 65: 6228–6236. · DOI
- Streicher KL, Yang ZQ, Draghici S, Ethier SP . Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon. Oncogene 2007; 26: 2104–2114. · DOI
- Yan Y, Rubinchik S, Watson PM, Kelley JR, Fraser MM, Wood AL et al. Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinoma. Mol Ther 2005; 11: 363–372. · doi:10.1016/j.ymthe.2004.09.023
- Kelley JR, Brown JM, Frasier MM, Baron PL, Schweinfest CW, Vournakis JN et al. The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery 2000; 128: 353–360. · doi:10.1067/msy.2000.107605
- Kelley JR, Fraser MM, Schweinfest CW, Vournakis JN, Watson DK, Cole DJ . CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer. Surgery 2001; 130: 280–288. · doi:10.1067/msy.2001.115899
- Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107–1112. · DOI · Paper page
- Grutzmann R, Pilarsky C, Ammerpohl O, Luttges J, Bohme A, Sipos B et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 2004; 6: 611–622. · DOI · Paper page
- Segara D, Biankin AV, Kench JG, Langusch CC, Dawson AC, Skalicky DA et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 2005; 11: 3587–3596. · DOI · Paper page
- Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE . Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629–3637. · DOI · Paper page
- Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400–2407. · DOI · Paper page
- Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12: 4147–4153. · DOI · Paper page
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715. · DOI · Paper page
- Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A . Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008; 3: e2888. · DOI · Paper page
- Little EC, Wang C, Watson PM, Watson DK, Cole DJ, Camp ER . Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res 2012; 176: 359–366. · DOI
- Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK, Boylan AM . CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J Respir Cell Mol Biol 2008; 38: 671–678. · DOI
- Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 2004; 109: 182–188. · DOI
- Kurdow R, Schniewind B, Zoefelt S, Boenicke L, Boehle AS, Dohrmann P et al. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression. Langenbecks Arch Surg 2005; 390: 243–248. · doi:10.1007/s00423-004-0531-6
- Rodicker F, Stiewe T, Zimmermann S, Putzer BM . Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 2001; 61: 7052–7055.
- Takahashi S, Suzuki S, Inaguma S, Cho YM, Ikeda Y, Hayashi N et al. Down-regulation of Lsm1 is involved in human prostate cancer progression. Br J Cancer 2002; 86: 940–946. · doi:10.1038/sj.bjc.6600163
- Gumbs AA, Bassi C, Moore PS, Falconi M, Frigerio I, Baron A et al. Overexpression of the Sm-like proto-oncogene in primary and metastatic pancreatic endocrine tumors. J Pancreas 2002; 3: 109–115.
- Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997; 75: 388–395. · DOI · Paper page
- Hildenbrand R, Niedergethmann M, Marx A, Belharazem D, Allgayer H, Schleger C et al. Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol 2009; 174: 2246–2253. · DOI
- Rogers A, Smith MJ, Doolan P, Clarke C, Clynes M, Murphy JF et al. Invasive markers identified by gene expression profiling in pancreatic cancer. Pancreatology 2012; 12: 130–140. · DOI
- Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 2011; 11: 448. · DOI
- Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC . Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008; 36: 160–167. · doi:10.1097/mpa.0b013e31815750f0
- Hong SN, Lee JK, Choe WH, Ha HY, Park K, Sung IK et al. The effect of aberrant maspin expression on the invasive ability of pancreatic ductal adenocarcinoma cells. Oncol Rep 2009; 21: 425–430.
- Maass N, Hojo T, Ueding M, Luttges J, Kloppel G, Jonat W et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res 2001; 7: 812–817.
- Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelli M, Ballatore Z et al. Role of maspin in cancer. Clin Transl Med 2013; 2: 8. · DOI
- Bachmann J, Buchler MW, Friess H, Martignoni ME . Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer 2013; 65: 827–833. · DOI
- Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME . Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008; 12: 1193–1201. · DOI · Paper page
Cited by
Ren, Y., Yan, J., Han, X., Xu, C., Guo, M., Wang, X., Liu, C., Logrieco, A. F., Jin, Y., Ma, Z., et al. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag169 · Cited by 1
Metadata
- Authors
- Little, E. C., Camp, E. R., Wang, C., Watson, P. M., Watson, D. K., & Cole, D. J.
- Venue
- Oncogenesis
- Published
- 2016-01-11
- Volume
- 5
- Issue
- 1
- Pages
- e182-e182
- ISSN
- 2157-9024
- Cited by
- 31
- References
- 1
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. https://app.cochat.ai/papers/10.1038/oncsis.2015.45
- The paper
- Little, E. C., Camp, E. R., Wang, C., Watson, P. M., Watson, D. K., & Cole, D. J. (2016). The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. Oncogenesis. https://doi.org/10.1038/oncsis.2015.45
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.